Aromatic compounds

Global Losartan Market (2020 to 2026) - by Source, Form, Strength, Distribution Channel, Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Health, Pharmaceutical, Chemical compounds, Aromatic compounds, Angiotensin II receptor antagonists, Chloroarenes, Imidazoles, Losartan, Tetrazoles, Angiotensin II receptor blocker, Marketplace, Financial market

The Global Losartan Market is segmented based on source, form, strength, distribution channel, application, end-user, company and region.

Key Points: 
  • The Global Losartan Market is segmented based on source, form, strength, distribution channel, application, end-user, company and region.
  • To estimate and forecast the market size of the Global Losartan Market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast the Global Losartan Market based on source, form, strength, distribution channel, application, end-user, company and regional distribution.
  • To identify key sustainable strategies adopted by market players in the Global Losartan Market.

Outlook on the Graphene Global Market to 2031 - Featuring Adama Materials, Apex Graphene and Hycarb Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Other Manufacturing, Manufacturing, Graphene, Emerging technologies, Materials, Articles, Monolayers, Aromatic compounds, Matter, Potential applications of graphene, Hong Byung-hee

The Graphene Market Report 2021 contains:

Key Points: 
  • The Graphene Market Report 2021 contains:
    Unique market assessment tools to assess the viability of graphene, by market, and application.
  • Assessment of graphene by market including applications, key benefits, market megatrends, market drivers for graphene, technology drawbacks, competing materials, potential consumption of graphene to 2031 and main players.
  • Global graphene market size split by market in 2020and for each application to 2031.
  • Full list of technology collaborations, strategic partnerships, and M&As in the global graphene market including collaboration dates.

14 - Alpha Demethylase Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Health, Pharmaceutical, Chemical compounds, Aromatic compounds, Organic compounds, Chloroarenes, Pipeline, Dioxolanes, Tertiary alcohols, Imidazoles, Orphan drugs

The "14 - Alpha Demethylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "14 - Alpha Demethylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "14-alpha demethylase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in 14-alpha demethylase inhibitors pipeline landscape.
  • This segment of the report provides insights about the different 14-alpha demethylase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • 14-alpha demethylase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Cipla receives final approval for generic version of Sunovion Pharmaceuticals, Inc.'s Brovana® (Arformoterol Tartrate Inhalation Solution 15 mcg/ 2mL)

Retrieved on: 
Wednesday, June 23, 2021
Chemical compounds, Phenols, Formamides, Substituted amphetamines, Aromatic compounds, Service companies, Arformoterol, Sunovion, LinkedIn, IMS Health, Dosage form, Formoterol

Cipla's Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.'s Brovana.

Key Points: 
  • Cipla's Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.'s Brovana.
  • According to IQVIA (IMS Health), Brovana had US sales ofapproximately $438M for the 12-month period ending April 2021.
  • Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets.
  • For more, please visit www.cipla.com , or click on Twitter , Facebook , LinkedIn .

Global Nanocatalysts, Nanocoatings, Nanofluids, and Graphene-Based Innovations Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 23, 2021
Technology, Nanotechnology, Emerging technologies, Nanomaterials, Materials, Articles, Matter, Graphene, Monolayers, Aromatic compounds, Potential applications of graphene, Nanofluid, Nanotechnology

The "Growth Opportunities in Nanocatalysts, Nanocoatings, Nanofluids, and Graphene-Based Innovations" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Nanocatalysts, Nanocoatings, Nanofluids, and Graphene-Based Innovations" report has been added to ResearchAndMarkets.com's offering.
  • This issue of the Nanotechnology Opportunity Engine showcases innovations pertaining to graphene incorporated technologies, nanocoatings, and nanofluids.
  • The issue also emphasizes on certain attractive nanocatalysts currently trending in the chemicals manufacturing space.
  • Arci, Department of Science and Technology, India
    Daegu Gyeongbuk Institute of Science and Technology, South Korea

Cofttek Announces Mass-Production and Supply of Urolithin A & B

Retrieved on: 
Tuesday, June 15, 2021
Coumarins, Branches of biology, Phenols, Aromatic compounds, Urolithin, Ellagitannin, Ellagic acid, Gut microbiota, Skeletal muscle, Antioxidant, Muscle, Large intestine

With 5 years of research into ellagitannins, the source of urolithins, Cofttek is the only pharmaceutical facility in the world able to mass-produce Urolithin A & B.

Key Points: 
  • With 5 years of research into ellagitannins, the source of urolithins, Cofttek is the only pharmaceutical facility in the world able to mass-produce Urolithin A & B.
  • Following 5 years of research, Cofttek has become the only facility in the world able to mass-produce Urolithin A & B.
  • Urolithin B has anti-inflammatory and antioxidant properties and is also a regulator of skeletal muscle mass.
  • Ellagitannins are converted by the human gut microflora into ellagic acid which is further transformed into urolithins A, urolithin B, urolithin C and urolithin D in the large intestines.

AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

Retrieved on: 
Monday, June 7, 2021
Chemical compounds, Organic compounds, Aromatic compounds, Tyrosine kinase receptors, Lung cancer, ROS1, Crizotinib, Non-small-cell lung carcinoma, Entrectinib, ALK inhibitor

The results were as follows:

Key Points: 
  • The results were as follows:
    In the crizotinib pre-treated patients (n=5), the ORR was 60% (3/5); and the DCR was 100% (5/5).
  • Our team is highly focused on completing patient enrollment for this phase II TRUST trial in Q3 2021, said Bing Yan, MD, Co-founder and Chief Medical Officer of AnHeart.
  • We sincerely thank the patients, their families and investigators in the TRUST trial and look forward to bringing taletrectinib to all ROS1 fusion positive patients in the near future upon approval.
  • Taletrectinib has shown good efficacy and safety results, which offers hope to patients with ROS1 fusion positive non-small cell lung cancer."

Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Organic compounds, Chemical compounds, Aromatic compounds, Lung cancer, Chloroarenes, Quinazolines, Aromatic amines, Tyrosine kinase receptors, Neratinib, Tyrosine kinase inhibitor, Epidermal growth factor receptor, Non-small-cell lung carcinoma

The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study that includes a cohort evaluating the safety and efficacy of neratinib administered daily to patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC).

Key Points: 
  • The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study that includes a cohort evaluating the safety and efficacy of neratinib administered daily to patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC).
  • A cohort of 11 patients with EGFR exon 18-mutant NSCLC from the Phase II SUMMIT basket trial, including patients with central nervous system involvement, were evaluated for safety and efficacy.
  • Prior lines of therapies included EGFR tyrosine kinase inhibitors (TKIs) (91%), chemotherapy (55%) and checkpoint inhibitors (IOs) (27%).
  • These results suggest that neratinib can be a potential treatment option for patients with NSCLC and hard-to-treat CNS metastases.

AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma

Retrieved on: 
Wednesday, May 19, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical trials, Organic compounds, Chemical compounds, Aromatic compounds, Chloroarenes, Ureas, Pyridines, Sorafenib, FOTIVDA® (tivozanib), Advanced Renal Cell Carcinoma, AVEO Pharmaceuticals, Inc., FOTIVDA® (TIVOZANIB), ADVANCED RENAL CELL CARCINOMA, AVEO PHARMACEUTICALS, INC.

\xe2\x80\x9cWe were also pleased to see efficacy advantages relative to sorafenib were maintained or improved with longer follow-up.

Key Points: 
  • \xe2\x80\x9cWe were also pleased to see efficacy advantages relative to sorafenib were maintained or improved with longer follow-up.
  • Additional analyses and long-term follow up results from the TIVO-3 study to be presented at the 2021 ASCO Annual Meeting include:\nDurability of Response and Updated Overall Survival.
  • It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Organic compounds, Chemical compounds, Puma Biotechnology, Aromatic compounds, Quinolines, Asco, Neratinib, Puma, American Society of Clinical Oncology

b'Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of three abstracts on neratinib for the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8, 2021.

Key Points: 
  • b'Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of three abstracts on neratinib for the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8, 2021.
  • Puma will present three posters with audio recordings, the corresponding abstracts of which are now live on the 2021 ASCO Annual Meeting website.
  • Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
  • NERLYNX is a registered trademark of Puma Biotechnology, Inc.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210519005103/en/\n'